PAM
RVNC

Premier Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Premier Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,092
Closed -$399K – 210
2020
Q4 		$399K Buy
14,092
+3,301
+31% +$85.5K 0.08% 114
2020
Q3 		$272K Buy
+10,791
New +$283K 0.07% 117
2019
Q3 		– Sell
-22,617
Closed -$293K – 150
2019
Q2 		$293K Buy
+22,617
New +$285K 0.07% 123

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Premier Asset Management's RVNC Position: Q1 2021 in Review

Premier Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2021, closing a stake of 14,092 shares — an estimated $399K sold.

Premier Asset Management first reported a position in RVNC in Q2 2019 and held it in 3 quarters. The position peaked at $399K in Q4 2020. 149 funds tracked by Wall St. Rank hold RVNC as of Q1 2021.

  • Premier Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Premier Asset Management sold 14,092 Revance Therapeutics, Inc. shares in Q1 2021, an estimated $399K.
  • Premier Asset Management first reported a position in Revance Therapeutics, Inc. in Q2 2019 and held it in 3 quarters.
  • Premier Asset Management's Revance Therapeutics, Inc. position peaked at $399K in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2021.

Based on Premier Asset Management's 13F filing for Q1 2021, filed 12 May 2021.